FDA approves AstraZeneca drug for heart failure risk
21st Oct 2019 07:16
(Sharecast News) - AstraZeneca on Monday announced that its Farxiga treatment against heart failure risk in certain patient groups has received approval from the US Food and Drug Administration.
Read moreAstraZeneca breast cancer drug candidate clears FDA hurdle
17th Oct 2019 07:37
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo Company, announced on Thursday that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for trastuzumab deruxtecan, or DS-8201, and granted it 'Priority Review' status.
Read moreTuesday broker round-up
15th Oct 2019 12:47
(Sharecast News) - Ocado: JP Morgan downgrades to underweight with a target price of 1,050p.
Read moreWednesday broker round-up
9th Oct 2019 12:51
(Sharecast News) - Volution Group: Peel Hunt upgrades to buy with a target price of 200p.
Read moreAstraZeneca asthma drug wins US regulatory approval for self-administration
4th Oct 2019 07:21
(Sharecast News) - AstraZeneca said on Friday that the US Food and Drug Administration has approved the self-administration of its Fasenra (benralizumab) for patients with severe eosinophilic asthma.
Read moreAstraZeneca offloads Losec rights, advances PT010 in US
1st Oct 2019 07:28
(Sharecast News) - AstraZeneca has agreed to sell the global commercial rights for Losec (omeprazole) and its associated brands, excluding China, Japan, the US and Mexico, to Cheplapharm Arzneimittel, it announced on Tuesday.
Read moreAstraZeneca upbeat on latest Tagrisso and Lynparza results
30th Sep 2019 09:20
(Sharecast News) - AstraZeneca released overall survival results from the phase 3 'FLAURA' trial of Tagrisso (osimertinib) in the first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) on Monday.
Read moreAstraZeneca takes control of Linzess collaboration with Ironwood
18th Sep 2019 07:12
(Sharecast News) - AstraZeneca confirmed on Wednesday that it will take on responsibility for the development, manufacture and commercialisation of Linzess in China, Hong Kong and Macau after amending an agreement with Ironwood Pharmaceuticals.
Read moreFriday broker round-up
13th Sep 2019 12:49
(Sharecast News) - Britvic: Jefferies upgrades to buy with a target price of 1000p.
Read moreWednesday broker round-up
11th Sep 2019 13:12
(Sharecast News) - Renew Holdings: Peel Hunt initiates at buy with a target price of 500p.
Read moreCiti reiterates 'buy' on AstraZeneca, says new drugs under-appreciated
11th Sep 2019 10:57
(Sharecast News) - Citi reiterated its 'buy' rating AstraZeneca on Wednesday, lifting the price target to 10,000p from 7,000 as it said the market continues to under-appreciate the commercial potential and operating leverage from drugs such as Tagrisso, Lynparza, roxadustat and Farxiga.
Read moreAstraZeneca's Imfinzi improves patient survival in lung cancer trial
9th Sep 2019 14:34
(Sharecast News) - AstraZeneca on Monday reported that its Imfinzi drug had improved overall survival by almost three months in patients with late-stage small cell lung cancer in a recent trial.
Read moreJP Morgan stays at 'overweight' on AstraZeneca, sees further re-rating ahead
5th Sep 2019 16:27
(Sharecast News) - Analysts at JP Morgan told clients to continue to overweight big market capitalisation stocks versus their smaller mid-cap peers over the next six months.
Read moreAstraZeneca receives Chinese marketing approval for Tagrisso
4th Sep 2019 08:20
(Sharecast News) - Biopharmaceutical giant AstraZeneca has received marketing authorisation for its lung cancer treatment Tagrisso from China's National Medical Products Administration.
Read moreMonday broker round-up
2nd Sep 2019 13:16
(Sharecast News) - Beazley: UBS upgrades to buy with a target price of 650p.
Read more